Global Breast Lesion Localization Research Report 2023-2028: Advancements in Imaging Technology Fuel Detection of Clinically Occult Breast Lesions, Propelling Localization Market

The “Breast Lesion Localization Market by Type (Wire, Radioisotope (ROLL, RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy, Lumpectomy), End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers) – Global Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.

The breast lesion localization market is expected to reach USD 387.4 million by 2028 from USD 278.1 million in 2023, at a CAGR of 6.9%.

The increasing screening of breast cancer through mammography and the increasing number of improvements in imaging technology have increased the detection of a non-palpable clinically occult breast lesion, which requires perioperative localization. There have been several technological advancements in breast lesion localization equipment in recent years aimed at improving patient safety, increasing efficiency, and reducing the cost of healthcare.

The growth of this market is mainly attributed to the growing incidence of breast cancer, the increasing rate of the geriatric population (as age is an important factor that increases the risk of breast cancer), the increasing number of breast cancer surgeries, and the rising awareness on the early detection of breast cancer in the coming years.

However, several factors, such as uncertainty in regulatory approval procedures, are expected to restrain the growth of the breast lesion localization market during the forecast period.

In 2022, Asia Pacific will grow at the highest CAGR during the forecast period. Major factors driving the growth of this market are rising prevalence of breast cancer, increasing healthcare expenditure, and the increasing number of awareness programs for the early detection of breast cancer in several APAC countries. Furthermore, rising government spending on breast cancer research and growing funding are also driving the market growth in APAC.

The prominent players in the breast lesion localization market include Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US).

Breast biopsy segment accounted for a larger share of the breast lesion localization market

In 2022, the breast biopsy segment accounted for a larger share of the breast lesion localization market.

The large share of this segment can be attributed to the increasing number of patients opting for breast biopsies across the world, the increasing rate of non-palpable breast lesions detected in screening programs, the rising number of breast cancer screening programs, the growing incidence of breast cancer, and an increase in awareness of early cancer detection.

The electromagnetic localization will grow at the highest CAGR during the forecast period

Based on type, the electromagnetic localization segment is estimated to grow at the highest during the forecast period.

The high growth of this segment can be attributed to factors such as reduction in surgical delays, improved patient satisfaction, optimal surgical planning, and no need for radioactive components. A recent development in the field of breast localization methods is the emergence of technologically advanced localization methods, which use electromagnetic waves to localize breast lesions.

Premium Insights

  • Rising Awareness About Breast Cancer and Increasing Government Initiatives Globally to Drive Market
  • Wire Localization Held Largest Share of Asia-Pacific Breast Lesion Localization Market in 2022
  • Asia-Pacific to Witness Highest Growth in Breast Lesion Localization Market During Forecast Period
  • North America to Dominate Breast Lesion Localization Market Till 2028
  • Emerging Economies to Register Higher Growth Rates During Study Period

Market Dynamics

Drivers

  • Increasing Incidence of Breast Cancer
  • Growth in Aging Population
  • Increasing Awareness on Early Detection of Breast Cancer

Restraints

  • Uncertainty in Regulatory Approval Procedures

Opportunities

  • High Growth Potential in Emerging Economies
  • Increasing Adoption of Technologically Advanced Localization Procedures

Challenges

  • Shortage of Oncologists

Industry Insights

Industry Trends

  • Electromagnetic Waves for Localization of Breast Lesions
  • Radiofrequency Identification in Breast Lesion Localization
  • Machine Learning Algorithms for Computer-Aided Breast Lesion Detection
  • Impact of Economic Recession on Breast Lesion Localization Market
  • Value Chain Analysis
  • Reimbursement Analysis

Technology Analysis

  • Key Technologies
  • Wire-Guided Localization (Wl)
  • Carbon Marking
  • Radioguided Occult Lesion Localization (Roll)
  • Radioactive Seed Localization (Rsl)
  • Magnetic Seed Localization (Msl)
  • Radiofrequency Reflector (Rfr)
  • Complementary Technologies
  • Mammography
  • 3D Mammography or Tomosynthesis
  • Magnetic Resonance Imaging
  • Ultrasound
  • Adjacent Technologies
  • Computer Vision and Artificial Intelligence

Case Study Analysis

  • Case Study 1: Estimating Market Size of Breast Lesion Localization Methods and Market Share Analysis for Key Products at Country Level
  • Case Study 2: Estimating Market Size of Breast Biopsy and Market Share Analysis for Key Products at Country Level

Company Profiles

Key Players

  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Merit Medical Systems
  • Leica Biosystems Nussloch GmbH
  • Argon Medical Devices
  • Laurane Medical LLC
  • Endomagnetics Ltd. (Endomag)
  • Intramedical Imaging, LLC
  • Isoaid
  • Surgiceye GmbH

Other Players

  • Ranfac Corp.
  • Mermaid Medical Group
  • Izi Medical Products, LLC
  • Matek Medikal
  • Tsunami Medical Srl
  • Bpb Medica
  • Sirius Medical Systems B.V.
  • Molli Surgical Inc.
  • Sterylab S.R.L.
  • Cp Medical
  • Mdl Srl
  • Biomedical Srl
  • Elucent Medical
  • Vigeo Srl
  • Medax Medical Devices

For more information about this report visit https://www.researchandmarkets.com/r/nu1qty

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”